


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Compounds of the formula I



in which

R^1, R^2 , independently of one another, denotes H, A, Hal, $(CH_2)_n$ Het, $(CH_2)_n$ Ar, cycloalkyl having 3 to 7 C atoms, CF_3 , NO_2 , CN, $C(NH)NOH$ or OCF_3 , OH, OA, NH_2 , NHA, NA_2 ,

Q denotes NR^3R^4 or Het,


R^3, R^4 denotes H, $(CH_2)_n$ Het, $(CH_2)_n$ Ar, A, cycloalkyl having 3 to 7 C atoms or CF_3 ,

R^5 denotes A, Ar or Het

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl or alkoxyalkyl having 2 to 10 C atoms,

Het denotes an organic heteroatom-containing radical, in particular a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic or linear or branched organic radical containing one or more hetero atoms which is unsubstituted or mono- or polysubstituted by A, cycloalkyl having 3 to 7 C atoms, OH, OA, NH_2 , NAH, NA_2 , NO_2 , CN and/or Hal,

Ar denotes an aromatic organic radical, in particular a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal, OR^5 , $OOCR^5$, $COOR^5$, $CON(R^5)_2$, CN, NO_2 , NH_2 , $NHCOR^5$, CF_3 , SO_2CH_3 or a ring-containing group $-OCH_2O-$,



n denotes 0, 1, 2, 3, 4 or 5

m denotes 1, 2 or 3


Hal denotes F, Cl, Br or I

and
denotes N or CH,

and salts and solvates, enantiomers, racemates thereof and other mixtures of the enantiomers, in particular physiologically tolerated salts and solvates thereof.

2. (Original) Compounds of the formula I according to Claim 1, in which R¹ denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl.
3. (Currently Amended) Compounds of the formula I according to Claim 1 ~~one or more of the preceding claims~~, in which R³ denotes H.
4. (Currently Amended) Compounds of the formula I according to Claim 1 ~~one or more of the preceding claims~~, in which R⁴ denotes H.
5. (Currently Amended) Compounds of the formula I according to Claim 1 ~~one or more of the preceding claims~~, in which R² denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinoliny, isoquinoliny, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl.
6. (Currently Amended) Compounds of the formula I according to Claim 1 ~~one or more of the preceding claims~~, in which X has the meaning N.


7. (Original) Compounds of the formula IA:



in which


R^1 , R^2 , R^5 and X have the meanings indicated in Claim 1.

8. (Original) Process for the preparation of compounds of the formula IA



in which R^1 , R^2 , R^5 and X have the meaning indicated in Claim 1

and salts and solvates thereof, which is characterised in that a compound of the formula II




or acid-addition salts thereof

in which

R^1 , R^2 and X have the meanings indicated in Claim 1,

is reacted with a compound of the formula III



III

in which

R⁵ has the meaning indicated in Claim 1,

and/or in that a basic compound of the formula IA is converted into one of its salts by treatment with an acid.

9. (Currently Amended) Compounds of the formula I according to Claim 1 ~~one or more of Claims 1 to 6~~ and physiologically acceptable salts and solvates thereof as medicaments.
10. (Currently Amended) Use of the compounds of the formula I according to Claim 1 ~~one or more of Claims 1 to 6~~, and salts and solvates thereof, for the preparation of a medicament for the treatment and prophylaxis of diseases which can be influenced by the binding of the compounds of the formula I to 5-HT receptors.
11. (Currently Amended) Use of compounds of the formula I according to Claim 1 ~~one or more of Claims 1 to 6~~ and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having a 5-HT receptor-antagonistic action.
12. (Currently Amended) Use of compounds of the formula I according to Claim 1 ~~one or more of Claims 1 to 6~~ and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having a 5-HT_{2A} receptor-antagonistic action.
13. (Currently Amended) Pharmaceutical composition characterised by a content of at least one compound of the formula I according to Claim 1 ~~one or more of Claims 1 to 6~~ and/or one of its physiologically acceptable salts and/or one of its solvates.
14. (Original) Process for the preparation of pharmaceutical compositions, characterised in that a compound of the formula I according to Claim 1 and/or one of its physiologically acceptable salts and/or one of its solvates is converted into a suitable dosage form together with at least one solid, liquid or

semi-liquid excipient or adjuvant.

15. (Currently Amended) Use of compounds of the formula according to Claim 1 ~~one or more of Claims 1 to 6~~ and/or physiologically acceptable salts or solvates thereof for the preparation of a medicament for the prophylaxis and/or treatment of psychoses, neurological disorders, amyotrophic lateral sclerosis, eating disorders, such as bulimia, anorexia nervosa, of premenstrual syndrome and/or for positively influencing obsessive-compulsive disorder (OCD).

16. (Original) Compounds of the formula I in which Het denotes one of the following radicals:

